SAN FRANCISCO, CA–(Marketwired – October 06, 2016) – Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical Inc. (NASDAQ: VIVE), which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women’s sexual function.
Included in this article is: Viveve Medical Inc.
The Life Sciences Report: Anthony, thank you for joining us. Would you tell us a little about yourself?
Anthony Vendetti: I’m director of research at Maxim Group, and I’m also a covering analyst. I’ve been following healthcare stocks for 22 years, and I have followed healthcare services stocks as well as device stocks. I also follow health and wellness companies. In the medical device area, I look at a lot of aesthetic companies as well as interesting emerging-growth medical device companies.
Viveve Medical Inc. fits into one of the trends we have been focused on for the last 10 to 12 years, which is the trend toward private-pay aesthetic procedures. When I say private pay, I mean nonreimbursable types of procedures. That trend has been growing. The companies that provide these types of aesthetic procedures have grown rapidly over the last 10 years.
Viveve has patented technology for tissue tightening that Thermage Inc. had for the face and body. It uses a particular energy source called monopolar capacitive-coupling radiofrequency, a type of radiofrequency that is efficacious for tissue tightening. Thermage sold that product for many years for the face, for wrinkles around the eyes, for tissue tightening on different parts of the body.
The founder of Thermage, Dr. Edward Knowlton, M.D., was able to acquire those patents for Viveve. Since then, Viveve has filed additional method patents and other patents for this technology for the treatment of vaginal tissue to improve sexual function.
Continue reading this article: Viveve’s Treatment for Improving Women’s Sexual Function May Leapfrog the Competition
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURE:
The following companies mentioned in this article are sponsors of Streetwise Reports: Viveve Medical Inc. The companies mentioned in this article were not involved in any aspect of the interview. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
Anthony Vendetti: I own, or members of my immediate household or family own, shares of the following companies mentioned in this interview: None. I am, or members of my immediate household or family are, paid by the following companies mentioned in this interview: None. See additional disclosures below. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I determined and had final say over which companies would be included in the interview based on my research, understanding of the sector and interview theme. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.
Please see the end of the article for the complete disclosure: Viveve’s Treatment for Improving Women’s Sexual Function May Leapfrog the Competition
Contact Information:
Carrie Beal Amaro
Associate Publisher
Email contact
